The association of renal cell carcinoma with gastrointestinal stromal tumors

Prior small studies have reported a possible association between renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GISTs). In the largest known series, our objective was to describe the prevalence of RCC among patients with GISTs over 26 years at Memorial Sloan Kettering Cancer Center (MSKCC).

[1]  K. Søreide,et al.  Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. , 2016, Cancer epidemiology.

[2]  Yingyong Hou,et al.  A novel germline mutation in SDHA identified in a rare case of gastrointestinal stromal tumor complicated with renal cell carcinoma. , 2015, International journal of clinical and experimental pathology.

[3]  J. Sicklick,et al.  Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A population‐based study , 2015, Cancer.

[4]  David Y. Lu,et al.  Adult Patient with Synchronous Gastrointestinal Stromal Tumor and Xp11 Translocation-Associated Renal Cell Carcinoma: A Unique Case Presentation with Discussion and Review of Literature , 2015, Case reports in urology.

[5]  W. Hohenberger,et al.  Coexistence of gastrointestinal stromal tumours (GIST) and malignant neoplasms of different origin: prognostic implications. , 2014, International journal of surgery.

[6]  L. Lipton,et al.  Germline SDHC mutation presenting as recurrent SDH deficient GIST and renal carcinoma. , 2013, Pathology.

[7]  I. Codreanu,et al.  Gastrointestinal stromal tumor of small intestine and synchronous bilateral papillary renal cell carcinoma. , 2013, Connecticut medicine.

[8]  J. Blay,et al.  Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing , 2011, PloS one.

[9]  A. Bilici,et al.  Co-existence of gastrointestinal stromal tumors with other primary neoplasms. , 2011, Hepato-gastroenterology.

[10]  W. Linehan,et al.  The genetic basis of kidney cancer: a metabolic disease , 2010, Nature Reviews Urology.

[11]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Mazzucchelli,et al.  Epidemiology and molecular biology of gastrointestinal stromal tumors (GISTs): a population-based study in the South of Switzerland, 1999-2005. , 2008, Histology and histopathology.

[13]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[14]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[15]  R. Motzer,et al.  Sunitinib in patients with metastatic renal cell carcinoma. , 2006, JAMA.

[16]  L. Sobin,et al.  Occurrence of other malignancies in patients with gastrointestinal stromal tumors. , 2006, Seminars in diagnostic pathology.

[17]  B. Nilsson,et al.  Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era , 2005, Cancer.

[18]  J. Fletcher,et al.  Biology of gastrointestinal stromal tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  W. Au,et al.  Papillary renal cell carcinoma and gastrointestinal stromal tumor: a unique association. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  M. Ashcroft,et al.  Hypoxia‐inducible factor‐1 and oncogenic signalling , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[21]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Conaway,et al.  Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Scherer,et al.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.

[24]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[25]  M. Mazur,et al.  Gastric stromal tumors Reappraisal of histogenesis , 1983, The American journal of surgical pathology.

[26]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. DeMatteo,et al.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.

[28]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.